Overall, we analyzed the correlation between CD93 expression and prognosis, immune checkpoints, TME, immune cell infiltration levels, immune-related genes, functional enrichment, and immunotherapy in STAD. This evidence concerns the gene CD93 and gastric adenocarcinoma.